{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=74",
    "query": {
      "condition": "Phase I",
      "page": 74
    },
    "page_size": 10
  },
  "pagination": {
    "page": 74,
    "page_size": 10,
    "total_count": 18752,
    "total_pages": 1876,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=75&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=73&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T14:27:56.218Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04696393",
      "title": "A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Mitapivat tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 26,
      "start_date": "2021-01-06",
      "completion_date": "2021-03-19",
      "has_results": false,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-11-12T14:27:56.218Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04696393"
    },
    {
      "nct_id": "NCT02766621",
      "title": "Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-06823859",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo injection SC/IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 62,
      "start_date": "2016-05-27",
      "completion_date": "2017-09-26",
      "has_results": false,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-11-12T14:27:56.218Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02766621"
    },
    {
      "nct_id": "NCT03709914",
      "title": "PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pediatric ALL"
      ],
      "interventions": [
        {
          "name": "ZTI-01 100 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "ZTI-01 75 mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nabriva Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "Up to 11 Years"
      },
      "enrollment_count": 21,
      "start_date": "2018-05-24",
      "completion_date": "2026-01-10",
      "has_results": false,
      "last_update_posted_date": "2023-09-15",
      "last_synced_at": "2026-11-12T14:27:56.218Z",
      "location_count": 5,
      "location_summary": "Orange, California • San Diego, California • Louisville, Kentucky + 2 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03709914"
    },
    {
      "nct_id": "NCT00693433",
      "title": "Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "DS Stage I Multiple Myeloma",
        "DS Stage II Multiple Myeloma",
        "DS Stage III Multiple Myeloma",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2008-11-24",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-12T14:27:56.218Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00693433"
    },
    {
      "nct_id": "NCT01511081",
      "title": "Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "SBRT (stereotactic body radiotherapy)",
          "type": "RADIATION"
        },
        {
          "name": "SBPT (stereotactic body proton therapy)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2012-08",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2017-12-07",
      "last_synced_at": "2026-11-12T14:27:56.218Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01511081"
    },
    {
      "nct_id": "NCT06948019",
      "title": "Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HSP",
        "Hereditary Spastic Paraplegia",
        "Hereditary Spastic Paraparesis",
        "Hereditary Spastic Paraplegia Type 50",
        "Hereditary Spastic Paraplegia Type 47",
        "Hereditary Spastic Paraplegia Type 51",
        "Hereditary Spastic Paraplegia Type 52",
        "SPG47",
        "AP4B1",
        "Neurogenetic Disorders",
        "Neurodevelopmental Conditions",
        "Movement Disorders",
        "Gene Therapy"
      ],
      "interventions": [
        {
          "name": "BFB-101 (AAV9-CBh-AP4B1)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BlackfinBio Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "60 Months",
        "sex": "ALL",
        "summary": "12 Months to 60 Months"
      },
      "enrollment_count": 5,
      "start_date": "2025-08",
      "completion_date": "2032-08",
      "has_results": false,
      "last_update_posted_date": "2025-04-28",
      "last_synced_at": "2026-11-12T14:27:56.218Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06948019"
    },
    {
      "nct_id": "NCT01100619",
      "title": "A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Papillary Thyroid Cancer",
        "Follicular Thyroid Cancer",
        "Huerthle Cell Thyroid Cancer",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "XL184",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2010-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-19",
      "last_synced_at": "2026-11-12T14:27:56.218Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Boston, Massachusetts • The Bronx, New York + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01100619"
    },
    {
      "nct_id": "NCT04493671",
      "title": "Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Disease",
        "Tuberculosis, Pulmonary",
        "Tuberculosis",
        "Multi Drug Resistant Tuberculosis",
        "Drug Sensitive Tuberculosis",
        "Drug-resistant Tuberculosis",
        "Mycobacterium Tuberculosis Infection"
      ],
      "interventions": [
        {
          "name": "TBAJ-876 suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo suspension",
          "type": "DRUG"
        },
        {
          "name": "TBAJ-876 100 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "TBAJ-876 25 mg tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 137,
      "start_date": "2020-06-08",
      "completion_date": "2022-11-15",
      "has_results": false,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-11-12T14:27:56.218Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04493671"
    },
    {
      "nct_id": "NCT03135509",
      "title": "A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "CC-220",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2017-05-24",
      "completion_date": "2017-06-28",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-11-12T14:27:56.218Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03135509"
    },
    {
      "nct_id": "NCT00379509",
      "title": "Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "lapatinib ditosylate",
          "type": "DRUG"
        },
        {
          "name": "TdT-mediated dUTP nick end labeling assay",
          "type": "GENETIC"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "microarray analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 20,
      "start_date": "2006-04",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2017-03-21",
      "last_synced_at": "2026-11-12T14:27:56.218Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00379509"
    }
  ]
}